OMNIBUS SOLICITATION OF THE
NATIONAL INSTITUTES OF HEALTH,
CENTERS FOR DISEASE CONTROL AND PREVENTION,
FOOD AND DRUG ADMINISTRATION, AND
ADMINISTRATION FOR CHILDREN AND FAMILIES FOR

SMALL BUSINESS INNOVATION
RESEARCH (SBIR)

AND

SMALL BUSINESS TECHNOLOGY
TRANSFER (STTR)

GRANT APPLICATIONS

NIH, CDC, FDA, and ACF Program Descriptions and
Research Topics

SUBMISSION DATES

SEPTEMBER 5, 2015, AND JANUARY 5, APRIL 5,
2016

National Institutes of Health (SBIR and STTR)
Centers for Disease Control and Prevention (SBIR)
Food and Drug Administration (SBIR)
Administration for Children and Families (SBIR)
NATIONAL CANCER INSTITUTE (NCI)

The National Cancer Institute (NCI) is committed to dramatically lessening the impact of cancer. The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs are NCI’s engines of innovation for developing and commercializing novel technologies to better prevent, diagnose, and treat cancer while enhancing cancer research and control. NCI’s SBIR and STTR Programs offer funding for therapeutic agents and devices; in vitro and in vivo diagnostics, including companion diagnostics and imaging agents; agents and technologies for cancer prevention; tools for research in cancer biology, cancer control, and epidemiology; digital health, including health information technology and bioinformatics; and many more areas of interest to the NCI.

NCI’s SBIR and STTR programs focus on research, development, and delivery of cancer technologies by funding small business concerns to conduct innovative research and development. The NCI SBIR Development Center is committed to helping small business concerns advance promising technologies towards the marketplace through funding as well as initiatives designed to facilitate external investments and commercialization. NCI is interested in following the progress of its funded small business concerns and the products they develop. Funding priority will be given to those small business concerns that show not only the ability to develop products but also growth towards independence from the SBIR/STTR programs.

The major NCI SBIR/STTR portfolio areas are listed below as a guide to general technology areas funded through the program. Applications proposing innovative cancer-related technologies, with strong commercial potential, that fall outside these topic areas are also encouraged through this Omnibus solicitation.

Major NCI SBIR/STTR Portfolio Areas:

- Therapeutics (e.g., Small Molecules, Biologics, Radiomodulators, and Cell-based Therapies)
- In Vitro and In Vivo Diagnostics (e.g., Companion Diagnostics and Prognostic Technologies)
- Imaging Technologies (e.g., Agents, Devices, and Image-Guided Interventions)
- Devices for Cancer Therapy (e.g., Interventional Devices, Surgical, and Radiation and Ablative Therapies)
- Tools for Cancer Biology Research
- Technologies and Agents for Cancer Prevention
- Technologies for Cancer Control (e.g., Behavioral Health Interventions, Tools for Genetic, Epidemiologic, Behavioral, Social, and/or Surveillance Cancer Research)
- Digital Health (e.g., Mobile Health, Health Information Technology, and Bioinformatics)

NCI particularly encourages applications in the following current research topics of interest:

- Development of Low Cost Technologies for Global Health
- Development of Companion Diagnostics
- Vaccine Development for Cancer Prevention
- Novel Technologies to Address “Undruggable” Drug Targets
- New Technologies to Assess Tissue-Based Markers of Tumor Death and Mitochondrial Stress in Response to Therapy
- Advances in Chimeric Antigen Receptor (CAR) Vector Engineering to Improve CARs Functionality and Safety
- Natural Language Processing (NLP) Applications to Electronic Health Records (EHR) to advance cancer prevention and control
- Automated Methods for Extraction and Consolidation of Cancer Registry Data
- Development of Novel Cancer Therapeutics Targeting Epigenetic Alterations
- Image-Guided Biopsy Platforms for Assessing Tumor Tissue Heterogeneity
- Cloud Computing Based Sharing, Integration and Analysis of Imaging Data for Cancer Diagnosis, Prognosis and Monitoring
- New Technologies for Ultrasensitive Molecular Histopathology

NCI accepts and encourages SBIR/STTR applications to support clinical trials.

For up-to-date information on high priority technology areas, and to learn about programmatic initiatives and upcoming events, visit the NCI SBIR Development Center homepage: [http://sbir.cancer.gov/](http://sbir.cancer.gov/).

In addition, please see the contact list at the end of the NCI section to identify the Program Director within the NCI SBIR Development Center who specializes in your technology area.

**Limited Amount of Award**

For budgetary, administrative, or programmatic reasons, NCI may decide not to fund an application or may decrease the length of an award and/or the budget recommended by a review committee. Generally, NCI will not fund Phase I applications greater than $225,000 total costs or project periods greater than 2 years; nor Phase II applications greater than $1,500,000 total costs or project periods greater than 3 years. For certain topical areas ([http://bit.ly/NCIwaiver](http://bit.ly/NCIwaiver)), the Small Business Administration has approved an NIH SBIR/STTR Topic Waiver list for which the NCI generally will not fund Phase I applications greater than $300,000 total costs or project periods greater than 2 years; nor Phase II applications greater than $2,000,000 total costs or project periods greater than 3 years. Applicants considering a requested budget greater than these limits are strongly encouraged to contact program staff before submitting an application.

**Phase IIB SBIR Competing Renewal Awards**

The NCI does not accept applications for Phase IIB SBIR competing renewal award through this Omnibus solicitation. However, the NCI offers Phase IIB opportunities in the form of the NCI SBIR Bridge Award, which is announced via a separate funding solicitation. The SBIR Bridge Award is designed to support the next stage of development for previously funded NIH-wide SBIR Phase II projects in the areas of cancer therapeutics, imaging technologies, interventional devices, diagnostics and prognostics. The purpose of this award is to address the funding gap known as the "Valley of Death" between the end of the SBIR Phase II award and the subsequent round of financing needed to advance a product or service toward commercialization. To achieve this goal, the Bridge Award funding opportunity is specifically designed to incentivize partnerships between NIH's SBIR Phase II awardees and third-party investors and/or strategic partners. Competitive preference and funding priority will be given to applicants that demonstrate the ability to secure substantial independent third-party investor funds (i.e., third-party funds that equal or exceed the requested NCI funds).

Budgets up to $1 million in total costs per year and project periods up to three years (a total of $3 million over three years) may be requested from the NCI. Development efforts may include preclinical R&D needed for regulatory filings (e.g., IND or IDE) and/or clinical trials. NCI intends to commit up to $10M for up to 10 new awards in FY2015.

To ensure that you will be notified upon the release of the NCI SBIR Phase IIB Bridge Award solicitation, please sign up for the [NCI SBIR mailing list](mailto:). If you have any questions regarding the Bridge Award, please contact your Phase II program director.

**For additional information about the NCI SBIR/STTR programs, please contact the NCI SBIR Development Center:**

Small Business Innovation Research (SBIR) Development Center
National Cancer Institute
9609 Medical Center Drive  
Rockville, MD  20850  
Website: http://sbir.cancer.gov  
Email: NCIbsbir@mail.nih.gov  
Phone: 240-276-5300

For additional information on research topics, please contact a Program Officer with the relevant area of expertise:

Michael Weingarten, MA  
Director, NCI SBIR Development Center  
Email: weingartenm@mail.nih.gov

Gregory Evans, PhD  
Program Director and Team Leader  
Email: evansgl@mail.nih.gov

Areas of expertise: Therapeutics (Immunotherapy, Gene Therapy), Cancer Imaging, Cancer Control, Tools for Cancer Biology Research, and Digital Health

Andrew Kurtz, PhD  
Program Director and Team Leader  
Email: kurtza@mail.nih.gov

Areas of expertise: Therapeutics (Small Molecules, Biologics, Nanotherapeutics), and Molecular Diagnostics

Patricia Weber, DrPH  
Program Director  
Email: weberpa@mail.nih.gov

Areas of expertise: Digital Health and Therapeutics (Small Molecules, Biologics, Immunotherapy)

Xing-Jian Lou, PhD  
Program Director  
Email: loux@mail.nih.gov

Areas of expertise: In Vitro Diagnostics and Therapeutics (Gene Therapy)

Deepa Narayanan, MS, CCDM  
Program Director  
Email: narayanand@mail.nih.gov

Areas of expertise: Radiation Therapy, Cancer Imaging, Medical Devices, and Clinical Trials

Amir Rahbar, PhD, MBA  
Program Director  
Email: amir.rahbar@nih.gov

Areas of expertise: In Vitro Diagnostics, Proteomics, and Therapeutics (Biologics)

Todd Haim, PhD  
Program Director  
Email: haimte@mail.nih.gov
Areas of expertise: Therapeutics (Small Molecules, Biologics, Immunotherapy) and Cancer Prevention

Ming Zhao, PhD  
Program Director  
Email: zhaoming3@mail.nih.gov

Areas of expertise: *In Vitro* Diagnostics, Cancer Stem Cells, Molecular Imaging, Bioinformatics, Therapeutics (Small Molecules, Biologics, Immunotherapy), and Cancer Control (Community-Based Participatory Research)

Jonathan Franca-Koh PhD, MBA  
Program Director  
Email: jonathan.franca-koh@nih.gov

Areas of expertise: Cancer Biology, Biologics, Small Molecules, Cell Based Therapies

For administrative and grants management questions, please contact:

Jacquelyn Boudjeda  
Grants Management Specialist  
Office of Grants Administration  
National Cancer Institute  
9609 Medical Center Drive  
West Tower, 2W514  
Rockville MD  20850  
Telephone: 240-276-6312  
Fax: (240) 276-7913  
Email: boudjedaj@mail.nih.gov